目的 初步探寻清开灵注射液治疗新型冠状病毒肺炎（COVID-19）的作用机制。方法 通过文献检索及中药系统药理学分析平台（TCMSP）得到清开灵注射液组方药材栀子、板蓝根、金银花等的活性成分及靶标蛋白。借助Uniprot数据库查询活性成分对应靶点基因，应用Cytoscape 3.7.2构建药物-化合物-靶点网络。借助DAVID数据库进行KEGG通路富集分析，预测其作用机制。对核心活性成分与抗COVID-19药物潜在作用靶点血管紧张素转化酶II（ACE2）、3C类似蛋白酶（3CLpro）、RNA依赖性RNA聚合酶（RdRp）进行分子对接验证。结果 药物-化合物-靶点网络共包含5种药物、62个化合物以及70个靶点。KEGG通路富集分析得到信号通路41条（P<0.05），主要涉及细胞凋亡、Fc epsilon RI信号通路、肿瘤坏死因子（TNF）信号通路等。分子对接结果显示，刺槐素、丁香苷等与抗COVID-19药物潜在作用靶点具有较强的亲和力。结论 清开灵注射液具有多成分、多靶点、多途径的作用特点，其活性成分刺槐素等可通过作用于CASP3、CASP8、FASLG等靶点调节细胞凋亡通路及TNF通路，从而实现对COVID-19的潜在治疗作用。

Objective To investigate the mechanism of Qingkailing Injection in the treatment of coronavirus disease 2019 (COVID-19). Methods The active components and target proteins of Gardeniae Fructus, Isatidis Radix, Lonicerae Japonicae Flos, and other materials in Qingkailing Injection were obtained by means of literature search and TCMSP. Uniprot database was used to search the target genes corresponding to the active ingredients, and Cytoscape 3.7.2 was used to construct the drug-compound-target network. The enrichment analysis of KEGG pathway was carried out with the help of DAVID database to predict its mechanism. Core active components and potential targets of anti-COVID-19 drugs were verified by molecular docking. Results The drug-compound-target network consisted of five drugs, 62 compounds and 70 targets. The KEGG pathway enrichment analysis included 41 signaling pathways (P<0.05), which were mainly involved in cell apoptosis, Fc epsilon RI signaling pathway, TNF signaling pathway, etc. Molecular docking results showed that acacetin and syrigin had strong affinity with potential targets of anti-COVID-19 drugs. Conclusion In this study, the effect of Qingkailing Injection has the characteristics of multiple components, multiple targets and multiple pathways. The active component, acacetin, can regulate the apoptosis pathway and TNF pathway by acting on CASP3, CASP8, FASLG, and other targets, so as to realize the potential therapeutic effect on COVID-19.

R285.5

国家重点研发计划项目（2017YFC1703900）；国家实验室药品监督管理局中成药质量评价重点实验室项目；成都中医药大学“杏林学者”学科人才科研提升计划新冠病毒应急专项（XGZX2010）